^
Association details:
| Biomarker: | TROP2 expression + HER-2 underexpression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | YH012 (HER2-targeted antibody-drug conjugate, Tubulin inhibitor, TROP-2-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate (YH012) exhibits potent anti-tumor efficacy
Published date:
04/04/2023
Excerpt:
YH012 exhibited superior anti-tumor efficacy than benchmark antibodies...In summary, YH012 has the advantages of increased potency, tissue specificity, and reduced toxicity as a novel BsADC that can be further exploited to treat HER2 and TROP2 co-expressing tumors, especially HER2-low tumors.
DOI:
10.1158/1538-7445.AM2023-2977
